백혈구성분채집술 시장 규모, 점유율, 동향 분석 보고서 : 제품 유형별, 용도별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Leukapheresis Market Size, Share & Trends Analysis Report By Product Type (Leukapheresis Devices, Leukapheresis Disposables), By Application (Research Application, Therapeutic Application), By End-use, By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,401,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,813,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,637,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

백혈구성분채집술 시장 규모와 동향:

전 세계 백혈구성분채집술 시장 규모는 2024년에 2억 1,130만 달러로 추정되며, 2025년부터 2030년까지 연평균 11.05%로 성장할 것으로 예상됩니다.

혈액 질환 및 자가 면역 질환의 유병률 증가, 백혈구성분채집술의 기술 발전, 맞춤형 의료에 대한 수요 증가가 시장 성장의 원동력이 될 것으로 예상됩니다. 또한, 연구개발 활동에 대한 투자가 증가하고 있는 것도 시장 성장에 기여하고 있습니다.

백혈병, 림프종과 같은 혈액 질환, 류마티스 관절염 및 다발성 경화증과 같은 자가 면역 질환의 발병률 증가는 시장 성장을 크게 촉진하고 있습니다. 예를 들어, Leukemia &Lymphoma Society(Leukemia &Lymphoma Society)의 보고서에 따르면, 2023년 미국에서는 총 184,720명이 백혈병, 림프종, 골수종 진단을 받을 것으로 예상됩니다. 마찬가지로, 2023년 5월, 2,200만 명을 대상으로 한 Lancet의 연구는 자가면역질환이 10명 중 1명꼴로 발병한다는 사실을 밝히고, 사회경제적, 계절적, 지역적 요인의 영향을 강조하며, 류마티스 관절염, 1형 당뇨병, 다발성 경화증을 포함한 이들 질환의 원인에 대한 인사이트를 제공하고 있습니다. 따라서 예측 기간 동안 백혈구성분채집술에 대한 수요를 촉진할 것입니다.

백혈구성분채집술 기술의 발전은 시술의 효율성, 안전성, 결과를 향상시키고 있습니다. 자동화 시스템, 연속 흐름 원심분리 시스템, 폐쇄형 시스템 장치의 도입은 백혈구성분채집술의 정확성과 효과를 향상시킬 것으로 예상됩니다. 2022년 10월, 미국혈액학회(ASFA)의 임상응용위원회는 IEC 치료 소위원회, AABB 및 기타 여러 단체와 함께 백서를 작성했습니다. 이 문서는 상업적 시도이든 연구 이니셔티브이든 간에 면역 이펙터 세포 치료의 일부인 소아 및 성인 환자에서 단핵구를 채취하는 백혈구성분채집술을 수행하기 위한 가이드라인을 설명합니다. 따라서 예측 기간 동안 시장 성장을 촉진할 것으로 예상됩니다.

환자 개개인의 특성에 맞게 치료 전략을 조정하는 개별화된 의료 접근 방식으로의 전환이 백혈구성분채집술에 대한 수요를 촉진하고 있습니다. 2023년 12월 Transfusion and Apheresis Science 저널에 게재된 논문은 말초혈액에서 백혈구를 채취하여 CAR-T 세포를 제조하는 CAR-T 세포 제조의 과제를 강조했습니다. 이 논문은 성공적인 CAR-T 세포 치료를 위해서는 효과적인 백혈구 채취가 중요한 역할을 한다는 점을 강조하며, T세포의 품질에 영향을 미치는 요인을 이해하는 것이 중요하다는 점을 강조했습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 백혈구성분채집술 시장 변수, 동향, 범위

• 시장 계통 전망
  • 상부 시장 전망
  • 관련/보조적인 시장 전망
• 시장 역학
  • 시장 견인 요인 분석
  • 시장 성장 억제요인 분석
• 백혈구성분채집술 시장 분석 툴
  • 업계 분석 - Porter's Five Forces 분석
  • PESTEL 분석
  • COVID-19의 영향 분석

제4장 백혈구성분채집술 시장 : 제품 유형 추정·동향 분석

• 부문 대시보드
• 세계의 백혈구성분채집술 시장 제품 유형 변동 분석
• 세계의 백혈구성분채집술 시장 규모와 동향 분석, 제품 유형별, 2018-2030년
• 백혈구성분채집술 기기
  • 원심분리 기기
  • 막분리 기기
• 백혈구성분채집술 일회용 제품

제5장 백혈구성분채집술 시장 : 용도 추정·동향 분석

• 부문 대시보드
• 세계의 백혈구성분채집술 시장 용도 변동 분석
• 세계의 백혈구성분채집술 시장 규모와 동향 분석, 용도별, 2018-2030년
• 조사 용도
  • 암 조사
  • 면역학 조사
  • 기타
• 치료 용도
  • 혈액질환
  • I 자가면역질환
  • 기타

제6장 백혈구성분채집술 시장 : 최종 용도 추정·동향 분석

• 부문 대시보드
• 세계의 백혈구성분채집술 시장 최종 용도 변동 분석
• 세계의 백혈구성분채집술 시장 규모와 동향 분석, 최종 용도별, 2018-2030년
• 혈액 센터
• 학술조사기관
• 제약·바이오테크놀러지 기업
• 병원·클리닉

제7장 백혈구성분채집술 시장 : 제품 유형, 용도, 최종 용도별 지역 추정·동향 분석

• 지역별 시장 점유율 분석, 2024년 및 2030년
• 지역 시장 대시보드
• 시장 규모와 예측 동향 분석, 2018년에서 2030년 :
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 노르웨이
  • 스웨덴
  • 덴마크
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트
  • 쿠웨이트

제8장 경쟁 구도

• 기업/경쟁 분류
• 전략 매핑
• 기업 시장 상황 분석, 2024년
• 기업 개요/상장 기업
  • Charles River Laboratories International, Inc.
  • Adacyte Therapeutics
  • AllCells, LLC
  • Asahi Kasei Medical
  • Haemonetics Corporation
  • Macopharma
  • Cerus Corporation
  • SB-Kawasumi Laboratories, Inc.
  • StemExpress, LLC.
  • Caltag Medsystems Limited
  • Lonza Group AG
  • ZenBio
  • Terumo BCT, Inc.
  • Macopharma SA
  • Miltenyi Biotec
  • Fresenius SE &Co. KGaA
  • Guangzhou Daji Medical Science
  • MEDICA SpA
  • SB-Kawasumi Laboratories, Inc.
  • PuriBlood Medical Co. Ltd.
  • Beijing ZKSK Technology Co. Ltd.

ksm

영문 목차

영문목차

Leukapheresis Market Size & Trends:

The global leukapheresis market size was estimated at USD 211.3 million in 2024 and is projected to grow at a CAGR of 11.05% from 2025 to 2030. The increasing prevalence of blood disorders and autoimmune diseases, technological advancements in leukapheresis procedures, and growing demand for personalized medicine are expected to drive the market growth. Moreover, the increasing investments in research and development activities are further contributing to the market growth.

The rising incidence of blood disorders like leukemia, lymphoma, and autoimmune diseases such as rheumatoid arthritis and multiple sclerosis are significantly driving the market growth. For instance, the Leukemia & Lymphoma Society reports that an estimated total of 184,720 people in the U.S. are expected to receive a diagnosis of leukemia, lymphoma, or myeloma in 2023. Similarly, in May 2023, a study in The Lancet involving 22 million people found autoimmune disorders affect 1 in 10 individuals, highlighting the influence of socioeconomic, seasonal, and regional factors and offers insights into the causes of these diseases, including Rheumatoid arthritis, Type 1 diabetes, and Multiple sclerosis. Thus, propelling the demand for leukapheresis over the forecast period.

The advancements in leukapheresis technologies are improving the efficiency, safety, and outcomes of the procedure. The introduction of automated systems, continuous flow centrifugation systems, and closed-system devices is expected to enhance the precision and effectiveness of leukapheresis. Thereby reducing the procedure times, minimizing donor discomfort, and optimizing cell collection yields. In October 2022, the Clinical Applications Committee of The American Society for Apheresis (ASFA), along with the IEC Therapy Subcommittee, AABB, and various other organizations, prepared a white paper. This document outlines guidelines for performing leukapheresis to retrieve mononuclear cells from pediatric and adult patients who are part of immune effector cell therapies, whether for commercial endeavors or research initiatives. Thus, anticipated to propel the market growth over the forecast period.

The shift towards personalized medicine approaches that tailor treatment strategies to individual patient profiles is fueling the demand for leukapheresis procedures. Leukapheresis plays a crucial role in cell-based therapies, such as chimeric antigen receptor (CAR) T-cell therapy and stem cell transplantation. In December 2023, an article in Transfusion and Apheresis Science underscored the challenges in manufacturing CAR-T cells, beginning with the extraction of T cells through leukapheresis from peripheral blood. The article emphasized the critical role of an effective leukapheresis product in achieving successful CAR-T cell therapy and highlighted the significance of comprehending the factors that impact T cell quality.

Global Leukapheresis Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global leukapheresis market report based on product type, application, end-use, and region:

• Product Type Outlook (Revenue, USD Million, 2018 - 2030)
• Leukapheresis Devices
  • Centrifugal Devices
  • Membrane Separators
• Leukapheresis Disposables
• Application Outlook (Revenue, USD Million, 2018 - 2030)
• Research Application
  • Cancer Research
  • Immunology Research
  • Others
• Therapeutics Application
  • Hematologic Disorders
  • Autoimmune Diseases
  • Others
• End-use Outlook (Revenue, USD Million, 2018 - 2030)
• Blood Centers
• Academic & Research Institutes
• Pharmaceutical & Biotechnology Companies
• Hospitals & Clinics
• Regional Outlook (Revenue, USD Million, 2018 - 2030)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• MEA
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
  • 1.2.1. Product Type
  • 1.2.2. Application
  • 1.2.3. End Use
• 1.3. Information analysis
• 1.4. Market formulation & data visualization
• 1.5. Data validation & publishing
• 1.6. Information Procurement
  • 1.6.1. Primary Research
• 1.7. Information or Data Analysis
• 1.8. Market Formulation & Validation
• 1.9. Market Model
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Leukapheresis Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. The increasing prevalence of blood disorders and autoimmune diseases
    • 3.2.1.2. Technological advancements in leukapheresis procedures
    • 3.2.1.3. Growing demand for personalized medicine
    • 3.2.1.4. Rising investments in research
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High equipment costs
• 3.3. Leukapheresis Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Leukapheresis Market: Product Type Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Leukapheresis Market Product Type Movement Analysis
• 4.3. Global Leukapheresis Market Size & Trend Analysis, by Product Type, 2018 to 2030 (USD Million)
• 4.4. Leukapheresis Devices
  • 4.4.1. Leukapheresis devices market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4.2. Centrifugal Devices
    • 4.4.2.1. Centrifugal Devices market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4.3. Membrane Separators
    • 4.4.3.1. Membrane separators market estimates and forecasts, 2018 to 2030 (USD Million)
• 4.5. Leukapheresis Disposables
  • 4.5.1. Leukapheresis disposables market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Leukapheresis Market: Application Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Leukapheresis Market Application Movement Analysis
• 5.3. Global Leukapheresis Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
• 5.4. Research Application
  • 5.4.1. Research application market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4.2. Cancer Research
    • 5.4.2.1. Cancer research market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4.3. Immunology Research
    • 5.4.3.1. Immunology research market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4.4. Others
    • 5.4.4.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.5. Therapeutics Application
  • 5.5.1. Therapeutics application market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.5.2. Hematologic Disorders
    • 5.5.2.1. Hematologic disorders market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.5.3. I Autoimmune Diseases
    • 5.5.3.1. Autoimmune diseases market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.5.4. Others
    • 5.5.4.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Leukapheresis Market: End Use Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Leukapheresis Market End Use Movement Analysis
• 6.3. Global Leukapheresis Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
• 6.4. Blood Centers
  • 6.4.1. Blood centers institutes market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.5. Academic & Research Institutes
  • 6.5.1. Academic & research institutes market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.6. Pharmaceutical & Biotechnology Companies
  • 6.6.1. Pharmaceutical & biotechnology companies market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.7. Hospitals & Clinics
  • 6.7.1. Hospitals & clinics market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. Leukapheresis Market: Regional Estimates & Trend Analysis by Product Type, Application, and End Use

• 7.1. Regional Market Share Analysis, 2024 & 2030
• 7.2. Regional Market Dashboard
• 7.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
• 7.4. North America
  • 7.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.4.2. U.S.
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Regulatory framework
    • 7.4.2.3. Competitive scenario
    • 7.4.2.4. U.S. market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.4.3. Canada
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Regulatory framework
    • 7.4.3.3. Competitive scenario
    • 7.4.3.4. Canada market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.4.4. Mexico
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Regulatory framework
    • 7.4.4.3. Competitive scenario
    • 7.4.4.4. Mexico market estimates and forecasts, 2018 to 2030 (USD Million)
• 7.5. Europe
  • 7.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.5.2. UK
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. UK market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.5.3. Germany
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. Germany market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.5.4. France
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Regulatory framework
    • 7.5.4.3. Competitive scenario
    • 7.5.4.4. France market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.5.5. Italy
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Regulatory framework
    • 7.5.5.3. Competitive scenario
    • 7.5.5.4. Italy market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.5.6. Spain
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Regulatory framework
    • 7.5.6.3. Competitive scenario
    • 7.5.6.4. Spain market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.5.7. Norway
    • 7.5.7.1. Key country dynamics
    • 7.5.7.2. Regulatory framework
    • 7.5.7.3. Competitive scenario
    • 7.5.7.4. Norway market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.5.8. Sweden
    • 7.5.8.1. Key country dynamics
    • 7.5.8.2. Regulatory framework
    • 7.5.8.3. Competitive scenario
    • 7.5.8.4. Sweden market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.5.9. Denmark
    • 7.5.9.1. Key country dynamics
    • 7.5.9.2. Regulatory framework
    • 7.5.9.3. Competitive scenario
    • 7.5.9.4. Denmark market estimates and forecasts, 2018 to 2030 (USD Million)
• 7.6. Asia Pacific
  • 7.6.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.6.2. Japan
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Japan market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.6.3. China
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Regulatory framework
    • 7.6.3.3. Competitive scenario
    • 7.6.3.4. China market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.6.4. India
    • 7.6.4.1. Key country dynamics
    • 7.6.4.2. Regulatory framework
    • 7.6.4.3. Competitive scenario
    • 7.6.4.4. India market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.6.5. Australia
    • 7.6.5.1. Key country dynamics
    • 7.6.5.2. Regulatory framework
    • 7.6.5.3. Competitive scenario
    • 7.6.5.4. Australia market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.6.6. South Korea
    • 7.6.6.1. Key country dynamics
    • 7.6.6.2. Regulatory framework
    • 7.6.6.3. Competitive scenario
    • 7.6.6.4. South Korea market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.6.7. Thailand
    • 7.6.7.1. Key country dynamics
    • 7.6.7.2. Regulatory framework
    • 7.6.7.3. Competitive scenario
    • 7.6.7.4. Thailand market estimates and forecasts, 2018 to 2030 (USD Million)
• 7.7. Latin America
  • 7.7.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.7.2. Brazil
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. Brazil market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.7.3. Argentina
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. Argentina market estimates and forecasts, 2018 to 2030 (USD Million)
• 7.8. MEA
  • 7.8.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.8.2. South Africa
    • 7.8.2.1. Key country dynamics
    • 7.8.2.2. Regulatory framework
    • 7.8.2.3. Competitive scenario
    • 7.8.2.4. South Africa market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.8.3. Saudi Arabia
    • 7.8.3.1. Key country dynamics
    • 7.8.3.2. Regulatory framework
    • 7.8.3.3. Competitive scenario
    • 7.8.3.4. Saudi Arabia market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.8.4. UAE
    • 7.8.4.1. Key country dynamics
    • 7.8.4.2. Regulatory framework
    • 7.8.4.3. Competitive scenario
    • 7.8.4.4. UAE market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.8.5. Kuwait
    • 7.8.5.1. Key country dynamics
    • 7.8.5.2. Regulatory framework
    • 7.8.5.3. Competitive scenario
    • 7.8.5.4. Kuwait market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Company/Competition Categorization
• 8.2. Strategy Mapping
• 8.3. Company Market Position Analysis, 2024
• 8.4. Company Profiles/Listing
  • 8.4.1. Charles River Laboratories International, Inc.
    • 8.4.1.1. Company overview
    • 8.4.1.2. Financial performance
    • 8.4.1.3. Product benchmarking
    • 8.4.1.4. Strategic initiatives
  • 8.4.2. Adacyte Therapeutics
    • 8.4.2.1. Company overview
    • 8.4.2.2. Financial performance
    • 8.4.2.3. Product benchmarking
    • 8.4.2.4. Strategic initiatives
  • 8.4.3. AllCells, LLC
    • 8.4.3.1. Company overview
    • 8.4.3.2. Financial performance
    • 8.4.3.3. Product benchmarking
    • 8.4.3.4. Strategic initiatives
  • 8.4.4. Asahi Kasei Medical
    • 8.4.4.1. Company overview
    • 8.4.4.2. Financial performance
    • 8.4.4.3. Product benchmarking
    • 8.4.4.4. Strategic initiatives
  • 8.4.5. Haemonetics Corporation
    • 8.4.5.1. Company overview
    • 8.4.5.2. Financial performance
    • 8.4.5.3. Product benchmarking
    • 8.4.5.4. Strategic initiatives
  • 8.4.6. Macopharma
    • 8.4.6.1. Company overview
    • 8.4.6.2. Financial performance
    • 8.4.6.3. Product benchmarking
    • 8.4.6.4. Strategic initiatives
  • 8.4.7. Cerus Corporation
    • 8.4.7.1. Company overview
    • 8.4.7.2. Financial performance
    • 8.4.7.3. Product benchmarking
    • 8.4.7.4. Strategic initiatives
  • 8.4.8. SB-Kawasumi Laboratories, Inc.
    • 8.4.8.1. Company overview
    • 8.4.8.2. Financial performance
    • 8.4.8.3. Product benchmarking
    • 8.4.8.4. Strategic initiatives
  • 8.4.9. StemExpress, LLC.
    • 8.4.9.1. Company overview
    • 8.4.9.2. Financial performance
    • 8.4.9.3. Product benchmarking
    • 8.4.9.4. Strategic initiatives
  • 8.4.10. Caltag Medsystems Limited
    • 8.4.10.1. Company overview
    • 8.4.10.2. Financial performance
    • 8.4.10.3. Product benchmarking
    • 8.4.10.4. Strategic initiatives
  • 8.4.11. Lonza Group AG
    • 8.4.11.1. Company overview
    • 8.4.11.2. Financial performance
    • 8.4.11.3. Product benchmarking
    • 8.4.11.4. Strategic initiatives
  • 8.4.12. ZenBio
    • 8.4.12.1. Company overview
    • 8.4.12.2. Financial performance
    • 8.4.12.3. Product benchmarking
    • 8.4.12.4. Strategic initiatives
  • 8.4.13. Terumo BCT, Inc.
    • 8.4.13.1. Company overview
    • 8.4.13.2. Financial performance
    • 8.4.13.3. Product benchmarking
    • 8.4.13.4. Strategic initiatives
  • 8.4.14. Macopharma SA
    • 8.4.14.1. Company overview
    • 8.4.14.2. Financial performance
    • 8.4.14.3. Product benchmarking
    • 8.4.14.4. Strategic initiatives
  • 8.4.15. Miltenyi Biotec
    • 8.4.15.1. Company overview
    • 8.4.15.2. Financial performance
    • 8.4.15.3. Product benchmarking
    • 8.4.15.4. Strategic initiatives
  • 8.4.16. Fresenius SE & Co. KGaA
    • 8.4.16.1. Company overview
    • 8.4.16.2. Financial performance
    • 8.4.16.3. Product benchmarking
    • 8.4.16.4. Strategic initiatives
  • 8.4.17. Guangzhou Daji Medical Science
    • 8.4.17.1. Company overview
    • 8.4.17.2. Financial performance
    • 8.4.17.3. Product benchmarking
    • 8.4.17.4. Strategic initiatives
  • 8.4.18. MEDICA S.p.A
    • 8.4.18.1. Company overview
    • 8.4.18.2. Financial performance
    • 8.4.18.3. Product benchmarking
    • 8.4.18.4. Strategic initiatives
  • 8.4.19. SB-Kawasumi Laboratories, Inc.
    • 8.4.19.1. Company overview
    • 8.4.19.2. Financial performance
    • 8.4.19.3. Product benchmarking
    • 8.4.19.4. Strategic initiatives
  • 8.4.20. PuriBlood Medical Co. Ltd.
    • 8.4.20.1. Company overview
    • 8.4.20.2. Financial performance
    • 8.4.20.3. Product benchmarking
    • 8.4.20.4. Strategic initiatives
  • 8.4.21. Beijing ZKSK Technology Co. Ltd.
    • 8.4.21.1. Company overview
    • 8.4.21.2. Financial performance
    • 8.4.21.3. Product benchmarking
    • 8.4.21.4. Strategic initiatives

관련자료